6533b83afe1ef96bd12a702c
RESEARCH PRODUCT
Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of Phase III trials
Philip J. JohnsonCiro CelsaGiorgio ErcolaniGiuseppe CabibboAndrea Casadei‐gardiniAlessandro CucchettiGiacomo Emanuele Maria RizzoCalogero Cammàsubject
SorafenibOncologyCancer Researchmedicine.medical_specialtyCarcinoma HepatocellularPhase iii trialsAntineoplastic AgentsDiseasesurvivaltime to progressionSystemic therapysystemic therapylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemeta-regressionmedicineHumansClinical TrialsMeta-regressionbusiness.industryCarcinomaLiver NeoplasmsHepatocellularhepatocellular carcinomaGeneral MedicineSorafenibmedicine.diseasePhase III as TopicSurvival RateTreatment Outcomehepatocellular carcinoma; meta-regression; sorafenib; survival; systemic therapy; time to progression; Antineoplastic Agents; Carcinoma Hepatocellular; Clinical Trials Phase III as Topic; Humans; Liver Neoplasms; Sorafenib; Survival Rate; Treatment OutcomeClinical Trials Phase III as TopicOncology030220 oncology & carcinogenesisHepatocellular carcinomaMeta-analysissorafenib030211 gastroenterology & hepatologybusinessmedicine.drugdescription
Aim: To benchmark overall survival (OS) and time to radiological progression (TTP) of patients enrolled in randomized controlled trials (RCTs) assessing sorafenib in advanced hepatocellular carcinoma using individual participant survival data, and to meta-analyze prognostic factors for OS and TTP. Methods: RCTs were identified through literature search until December 2018. Individual participant survival was reconstructed with an algorithm from published Kaplan–Meier curves. Results: Ten RCTs were included. Median OS was 10.0 months (95% CI: 9.6–10.5), and median TTP was 4.1 months (95% CI: 3.8–4.3). Multivariable analyses showed HCV positivity, absence of macrovascular invasion and extra-hepatic disease as predictors of longer OS. Conclusion: We provided a benchmark for future studies on sorafenib. The present results can be used in the decision making for the early shift to second-line strategy.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2019-01-01 |